Welcome to our dedicated page for Lifestance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on Lifestance Health Group stock.
LifeStance Health Group, Inc. (Nasdaq: LFST) is a mental healthcare company that focuses on outpatient services and regularly issues news and updates about its operations. The company describes itself as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults, and its news flow reflects both its clinical focus and its role as a public company.
On this page, readers can find news items such as quarterly earnings results, financial outlooks and operational metrics. LifeStance’s earnings releases discuss topics like revenue, visit volumes, clinician base, Center Margin, Adjusted EBITDA and Free Cash Flow, along with commentary from management on business performance and guidance. These updates provide insight into how the company’s outpatient mental health services translate into financial and operating results.
LifeStance also publishes announcements about participation in healthcare investor conferences hosted by organizations such as UBS, Morgan Stanley and Goldman Sachs. These releases typically include details about presentation dates, times and webcast availability, and they underscore the company’s ongoing engagement with the investment community.
In addition, LifeStance issues news related to corporate governance, including changes to its board of directors, and survey-based research on mental health topics. For example, the company has shared survey findings on how the holiday season affects mental health, addressing themes like seasonal stress, social pressure, loneliness and family dynamics. Together, these news items offer a view into LifeStance’s financial performance, strategic priorities and perspective on mental health trends.
Investors, analysts and others interested in LFST can use this news feed to follow the company’s regular earnings communications, conference appearances, governance updates and mental health surveys in one place.
LifeStance Health (NASDAQ:LFST) released a comprehensive survey revealing that 83% of Americans are experiencing "stressflation" - mental health impacts from financial stress driven by inflation and economic uncertainty. The study highlights a concerning trend where 60% of respondents are deterred from seeking mental health care due to financial constraints, up from 58% in 2024.
Key findings show that 47% of respondents have skipped therapy sessions due to cost, with millennials and Gen Z being most affected. However, there's a positive shift in care continuity, with 33% of patients returning to therapy within a week after a cost-related break in 2025, compared to just 8% in 2024. The survey also revealed that 93% of Americans view mental health care as equally important as physical health care.
LifeStance Health Group (NASDAQ: LFST), a leading outpatient mental health care provider, has scheduled its second quarter 2025 earnings release and conference call. The company will release its Q2 2025 financial results before market open on August 7, 2025, followed by a live earnings conference call at 8:30 a.m. Eastern Time.
Investors can join the call using the domestic dial-in number 1-800-715-9871 or international number 1-646-307-1963 with conference ID 1294873. A live audio webcast and related materials will be available through the Events and Presentations section of LifeStance's Investor Relations website, with a replay accessible after the call.
LifeStance Health Group (NASDAQ: LFST), a leading provider of outpatient mental health care, announced its participation in the 46th Annual Goldman Sachs Healthcare Conference in Miami, Florida. CEO Dave Bourdon and CFO Ryan McGroarty will present on Tuesday, June 10, 2025, at 10:40 a.m. Eastern time. The presentation, moderated by Jamie Perse, will be available via live webcast on the company's investor relations website, with a replay accessible after the event.
LifeStance Health (LFST) has appointed Vaughn Paunovich as its new Chief Technology Officer, effective June 9, 2025. Paunovich, who brings over 25 years of healthcare technology experience, will lead the company's end-to-end technology strategy. He previously served as EVP, Enterprise Platforms at Amwell and held leadership roles at UnitedHealth Group, including CIO of Optum Health.
Paunovich succeeds Pablo Pantaleoni, who is stepping down after joining in 2020 and leading the company's digital transformation efforts. The new CTO will focus on improving patient and clinician experience, increasing access to mental health services, and implementing scalable technologies aligned with LifeStance's mission of delivering virtual and in-person outpatient mental health care.
National Veterinary Associates (NVA) has announced key board appointments ahead of its planned IPO, naming Ken Burdick as Executive Chairman and Dr. Mike McFarland as Director. Burdick brings over 40 years of healthcare experience and currently serves as Executive Chairman at LifeStance Health (NASDAQ: LFST). He previously led WellCare Health Plans as CEO, delivering strong performance in revenue and profit margins before its acquisition by Centene Corporation.
Dr. McFarland contributes more than 40 years of veterinary healthcare expertise, including 11 years in senior leadership at Zoetis, Inc. and previous roles at Pfizer Animal Health. Greg Hartmann will remain on the board as a director, maintaining his investment in the company.
LifeStance Health Group (NASDAQ: LFST), a major outpatient mental health care provider, has scheduled its first quarter 2025 earnings release and conference call. The company will release Q1 2025 earnings before market opening on Wednesday, May 7, 2025, followed by a live earnings conference call at 8:30 a.m. Eastern Time.
Investors can participate by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) using conference ID 6060781. A real-time audio webcast will be available through the Events and Presentations section of LifeStance's Investor Relations website, with related materials posted before the call. A replay will be accessible afterward on the same platform.
LifeStance Health released a survey revealing concerning trends in social media's impact on mental health self-diagnosis. The study found that 29% of Americans self-diagnose mental health conditions based on social media content, with only 47% of these individuals consistently seeking professional guidance.
The survey highlighted that 54% of respondents encounter mental health misinformation weekly on social media, while 23% seek mental health advice on these platforms. Among generations, Gen Z (50%) and millennials (38%) lead in self-diagnosis rates.
Key findings show 26% of respondents check social media within five minutes of waking up, and 76% find the idea of a digital detox appealing. The study also revealed that 40% of respondents frequently encounter clinical terms like "trauma" and "narcissist" on social media, with 32% reporting that such content has led them to question their relationships.
LifeStance Health Group (Nasdaq: LFST) announced significant leadership changes, with Dave Bourdon appointed as the new CEO effective March 3, succeeding Ken Burdick who will transition to Executive Chairman. Bourdon, who joined as CFO in 2022, brings over two decades of healthcare and mental health industry experience.
Ryan McGroarty, with 25 years of healthcare experience including 15 years in CFO roles, will become the new Chief Financial Officer effective March 17. Under Burdick's leadership since September 2022, LifeStance has met or exceeded expectations for nine consecutive quarters.
Bourdon previously served as CFO of Magellan Health and held positions at Cigna, while McGroarty comes from Help at Home where he served as CFO and previously held multiple CFO roles at Cigna.
LifeStance Health Group (NASDAQ: LFST) reported strong financial results for Q4 and full year 2024. Full-year revenue grew 19% to $1.251 billion, while Q4 revenue increased 16% to $325.5 million.
Key highlights include:
- Clinician base grew 12% to 7,424, adding 779 clinicians in 2024
- Visit volumes rose 15% to 7.9 million for the full year
- Generated $107.3 million in operating cash flow
- Adjusted EBITDA doubled to $119.7 million
- Free Cash Flow reached $85.7 million
For 2025, LifeStance projects revenue between $1.40-1.44 billion and Adjusted EBITDA of $130-150 million. Q1 2025 guidance expects revenue of $320-340 million.
FAQ
What is the current stock price of Lifestance Health Group (LFST)?
What is the market cap of Lifestance Health Group (LFST)?
